Skip to main contentLast updated: 05-Nov-2026
Dr Harsh Shah
MS, MCh (Surgical Gastroenterology), DrNB (Surgical Gastroenterology)
Registered with Gujarat Medical Council, Reg. No. G-38738
Intestine Cancer Surgeon
Dr. Jivraj Mehta Hospital, Vasna, Ahmedabad · 18 years of experience
In short
No finished large trial decides the operation for small bowel cancer. None decides the chemotherapy after it, or the first drugs for spread disease. The one big trial built to answer the chemotherapy question did not fill its places.
Doctors rely instead on a few studies of different kinds. There is one early-phase drug study and one large patient cohort. There is one gene-mapping study, and some immunotherapy trials that enrol by tumour type.
Each kind of study carries a different weight. Knowing which one is being quoted tells you how much trust the advice deserves.
To see how these tumours are managed here, read our small bowel cancer treatment page. This post explains the studies behind that care.
The disease is rare, and rare cancers cannot fill large trials. A trial that takes a decade and many countries to recruit may still close short.
The result is that treatment here rests on borrowed evidence, and good doctors say so openly.
Five studies carry most of the weight. Each answers a different question, and none answers all of them.
| Study | Kind of study | What it told us |
|---|---|---|
| BALLAD | Randomised trial that did not fill its places | Meant to settle chemotherapy after surgery; the question is still open |
| Overman, 2009 | Early-phase study of a two-drug pair | The pair worked in spread disease, so it became the usual first choice |
| NADEGE | Large group of patients followed forward | Shows how the disease behaves and how it is treated today |
| Schrock, 2017 | Gene-mapping study of tumours | Showed the disease has its own gene pattern, with changes that can guide treatment |
| Le 2015, Le 2017 and KEYNOTE-158 | Immunotherapy trials open to many tumour types | Immunotherapy worked well for tumours with an MMR change |
Older registry reports, such as those by Bilimoria and Halfdanarson, give the background. They show how common each type is and how patients fared. They describe the disease. They do not test a treatment.
BALLAD asked a direct question: after surgery, does chemotherapy beat watching? It was designed to answer it, but recruitment was slow and no firm answer exists.
Until it reports, doctors offer chemotherapy after surgery when glands carry cancer, because colon cancer data point that way. For earlier stages the choice rests on risk signs. This is explained in our post on what the guidelines say.
For spread disease, the strongest prospective data is a single-arm study of capecitabine with oxaliplatin. It showed real activity, so it became the usual starting pair.
| It can show | It cannot show |
|---|---|
| The drugs shrink tumours in some patients | That they beat another drug pair |
| The side effects are acceptable | How long the benefit lasts compared with other options |
| A reason to try the pair first | That nothing better exists |
That is why the pair is a sensible default and not a proven winner.
With no big trial, a well-run group of patients followed over time becomes the next strongest evidence. NADEGE is that group for small bowel cancer.
It was not randomised, so it cannot prove that one treatment beats another. It is still respected, because it was careful and prospective. For how common the disease is and who gets it, see our post on how rare it is.
The 2017 gene-mapping study showed that small bowel cancer is its own disease. It is not just colon cancer higher up, and not just pancreas cancer in the duodenum.
Our post on tests and their order shows when these tissue tests are sent.
These trials did not enrol people by organ. They enrolled by the MMR change, and small bowel tumours were among those that responded.
| Study | What it did | Why it matters |
|---|---|---|
| Le, 2015 | Tested an immunotherapy drug by MMR status | First clear sign that the MMR change predicts a response |
| Le, 2017 | Widened this to many tumour types | Supported using the MMR test across organs |
| KEYNOTE-158 | Followed patients with tumours outside the colon | Lasting responses, and a basis for approval by tumour type |
Small studies that look only at the small bowel point the same way. Benefit gathers in tumours with the MMR change, and is much less likely in those without it. So the MMR result can outrank the usual first-choice drug pair.
Ask what kind of study is being quoted. A trial that randomised patients carries more weight than a single-arm study. A single-arm study carries more than one hospital’s records.
| Kind of study | Weight | Example here |
|---|---|---|
| Finished randomised trial | Highest | None exists for small bowel cancer |
| Randomised trial that did not report | Not usable yet | BALLAD |
| Study by tumour type, not organ | High, for tumours with the change | Le 2015, Le 2017, KEYNOTE-158 |
| Early-phase single-arm study | Moderate | Overman, 2009 |
| Large patient cohort | Moderate; strong for how the disease behaves | NADEGE |
| Gene-mapping study | High for biology, not for treatment | Schrock, 2017 |
| One hospital’s records | Lowest, as patients are selected | Halfdanarson, 2010 |
No single study should decide your care. Doctors weigh them together with your tumour tests and your health.
No. These studies are about the gland-forming cancer. The other three small bowel tumours have their own, richer trial evidence.
That is why the first step is always to confirm the tumour type from tissue. Applying a “no big trial” mindset to GIST or a neuroendocrine tumour would short-change the patient.
The trials were done mostly in the West, so they are borrowed here too. In India one more step comes first, which is to make sure the lump is not gut tuberculosis.
You can ask every one of these without sounding doubtful. A good team will answer plainly.
The answers help you weigh the advice. Where the evidence is thin, a clear statement of that is a sign of an honest plan.
No finished large trial exists. The disease is too rare to fill one. The main randomised trial built to test chemotherapy after surgery did not recruit enough patients. So doctors rely on smaller studies and on lessons from colon cancer.
It was an international trial that compared chemotherapy with watching after surgery, and asked whether adding oxaliplatin helps. It struggled to recruit, and no mature result is available to quote.
A prospective early-phase study showed that this pair was active in spread small bowel cancer. There is no head-to-head trial, so it is a sensible default and not a proven winner.
Immunotherapy trials open to many tumour types showed strong responses in tumours with an MMR change. Some were in the small bowel. The result can therefore change the first drug chosen.
Yes, when there is no randomised trial. A careful group of patients followed over time, such as NADEGE, shows how the disease behaves. It cannot prove that one treatment beats another because patients were not randomised.
No. These studies concern the gland-forming cancer. GIST, neuroendocrine tumours and lymphoma each have their own trials and their own treatment paths.
Trials are few, and tumour type and MMR status decide who is eligible. Ask your team at the tumour board whether one is open to you, and bring your tissue reports to the discussion.
For the full range of small bowel tumour care, start at the small bowel cancer treatment page. For questions before you travel, call +91-63555-64601.
Dr Harsh Shah — Dr. Jivraj Mehta Hospital, Vasna, Ahmedabad
Dr. Jivraj Mehta Hospital, Dr Jivraj Mehta Marg, Vasna, Ahmedabad 380007.
Consultations, review of reports and scans, operations and follow-up. OPD Monday to Saturday, 9 am to 5 pm.
Appointments: +91-63555-64601 · +91-63590-11009 · Hospital 079-2663 6363
Directions to the hospital · WhatsApp +91-63555-64601
Has someone quoted "a study" to support your small bowel cancer treatment, and you could not tell how strong it was? Bring the reports to Dr Harsh Shah. He will tell you which parts of your plan stand on firm ground and which stand on borrowed evidence. Call, or send a message on WhatsApp. Call +91-63555-64601 Ask on WhatsApp
Swasth Parivar: every week, practical advice on recovery, diet and warning signs. No advertising. Stop any time.
Your number is used for these updates and for the clinic to reach you. It is never sold or passed on. To stop, reply STOP on WhatsApp.